RT Journal Article
T1 Megacolon in inflammatory bowel disease: response to infliximab.
A1 Núñez Ortiz, Andrea
A1 Trigo Salado, Claudio
A1 de la Cruz Ramírez, María Dolores
A1 Márquez Galán, José Luis
A1 Herrera Justiniano, José Manuel
A1 Leo Carnerero, Eduardo
AB Megacolon is a serious complication of inflammatory bowel disease that often requires a colectomy. Infliximab is a therapeutic alternative when conventional treatment fails, before resorting to surgery. Its use is currently based on the publication of isolated cases. We present a series of 12 patients with megacolon treated with infliximab, five with signs of systemic toxicity. Seventy-five percent of the patients avoided a colectomy during their acute episode after early infliximab treatment, 2.45 days after the megacolon diagnosis. There was a greater risk of surgery among patients with ulcerative colitis and toxicity criteria. Two more patients required follow-up surgery despite long-term infliximab treatment. No patient suffered significant treatment-related adverse effects or significant post-surgery complications.
SN 1130-0108
YR 2020
FD 2020
LK http://hdl.handle.net/10668/14976
UL http://hdl.handle.net/10668/14976
LA en
DS RISalud
RD Apr 8, 2025